Nuvation Bio (NUVB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.18
- EPS estimate
- −$0.14
- EPS surprise
- −27.03%
- Revenue surprise
- +17.24%
- Revenue
- $31.7M
- Revenue estimate
- $27.0M
- Reported
- Aug 6, 2026
Nuvation Bio reported Q2 2026 results on August 6, 2026. The company posted a loss of $0.18 per share, wider than the $0.14 loss expected, a 27.03% miss. Revenue was $31.7 million, ahead of the $27.0 million consensus. Compared with Q2 2025, the loss was a little wider than $0.17 per share, while revenue rose from $4.8 million.
Nuvation Bio lost money in 19 of the 20 quarters in the table. The only profit was Q1 2026, at $0.01 per share. Annual losses were $0.48 per share in 2022, $0.34 in 2023, $2.26 in 2024 and $0.60 in 2025. Most of the 2024 loss came in Q2, at $1.89 per share. Revenue appears only from Q2 2024 and stayed below $6 million a quarter until Q3 2025, then rose to $13.1 million, $41.9 million and a high of $83.2 million in Q1 2026. 2025 revenue totalled $62.9 million. The company beat the EPS estimate in 10 of the 20 quarters.
Nuvation Bio reported Q3 results between November 2 and November 10 in each of the past five years. That points to early November 2026 for the next report. It will show where revenue settles after the uneven first half.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.14 | −$0.18 | −27.03% | $31.7M | SEC |
| Q1 2026 | May 4, 2026 | −$0.03 | $0.01 | +135.71% | $83.2M | SEC |
| Q4 2025 | Mar 2, 2026 | −$0.09 | −$0.11 | −23.60% | $41.9M | SEC |
| Q3 2025 | Nov 3, 2025 | −$0.17 | −$0.16 | +5.16% | $13.1M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.17 | −$0.17 | +0.00% | $4.8M | SEC |
| Q1 2025 | May 7, 2025 | −$0.15 | −$0.16 | −6.67% | $3.1M | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.13 | −$0.15 | −16.91% | $5.7M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.13 | −$0.15 | −19.05% | $727,000.00 | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.06 | −$1.89 | −3130.77% | $1.4M | SEC |
| Q1 2024 | May 14, 2024 | −$0.09 | −$0.07 | +23.66% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.10 | −$0.06 | +39.58% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.11 | −$0.09 | +14.29% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.11 | −$0.09 | +19.86% | $0.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.10 | −$0.10 | +0.10% | $0.00 | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.12 | −$0.10 | +15.68% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.14 | −$0.12 | +14.29% | $0.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.13 | −$0.16 | −20.39% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$0.14 | −$0.10 | +28.01% | $0.00 | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.12 | −$0.12 | −3.72% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.11 | −$0.11 | −4.46% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Nuvation Bio (NUVB) last report earnings?
Nuvation Bio last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did NUVB beat earnings estimates?
No. Nuvation Bio reported EPS of −$0.18 for Q2 2026 against a −$0.14 estimate — a 27.03% miss.
How much revenue did NUVB report last quarter?
Nuvation Bio reported $31.7M in revenue for Q2 2026, against a consensus estimate of $27.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.